Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis.

Sekine I, Segawa Y, Kubota K, Saeki T.

Cancer Sci. 2013 Jun;104(6):711-7. doi: 10.1111/cas.12146.

2.

Efficacy and safety of palonosetron as salvage treatment in the prevention of chemotherapy-induced nausea and vomiting in patients receiving low emetogenic chemotherapy (LEC).

Hesketh PJ, Morrow G, Komorowski AW, Ahmed R, Cox D.

Support Care Cancer. 2012 Oct;20(10):2633-7. doi: 10.1007/s00520-012-1527-3.

PMID:
22733373
3.
4.

Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study.

Hilarius DL, Kloeg PH, van der Wall E, van den Heuvel JJ, Gundy CM, Aaronson NK.

Support Care Cancer. 2012 Jan;20(1):107-17. doi: 10.1007/s00520-010-1073-9.

5.

Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.

Schwartzberg L, Jackson J, Jain G, Balu S, Buchner D.

Expert Rev Pharmacoecon Outcomes Res. 2011 Aug;11(4):481-8. doi: 10.1586/erp.11.47.

PMID:
21711119
6.

Effectiveness of palonosetron versus other serotonin 5-HT3 receptor antagonists in triple antiemetic regimens during multiday highly emetogenic chemotherapy.

Kim KI, Lee DE, Cho I, Yoon JH, Yoon SS, Lee HS, Oh JM.

Ann Pharmacother. 2012 Dec;46(12):1637-44. doi: 10.1345/aph.1R396.

PMID:
23170032
7.
8.

Palonosetron for prevention of acute and delayed nausea and vomiting in non-small-cell lung carcinoma patients.

Dong X, Huang J, Cao R, Liu L.

Med Oncol. 2011 Dec;28(4):1425-9. doi: 10.1007/s12032-010-9608-y.

PMID:
20602263
9.

Impact of initiating antiemetic prophylaxis with palonosetron versus ondansetron on risk of uncontrolled chemotherapy-induced nausea and vomiting in patients with lung cancer receiving multi-day chemotherapy.

Feinberg B, Gilmore J, Haislip S, Jackson J, Jain G, Balu S, Buchner D.

Support Care Cancer. 2012 Mar;20(3):615-23. doi: 10.1007/s00520-011-1140-x.

PMID:
21761096
11.

Antiemetic efficacy of single-dose palonosetron and dexamethasone in patients receiving multiple cycles of multiple day-based chemotherapy.

Lorusso V, Giampaglia M, Petrucelli L, Saracino V, Perrone T, Gnoni A.

Support Care Cancer. 2012 Dec;20(12):3241-6. doi: 10.1007/s00520-012-1469-9.

12.

Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.

Hajdenberg J, Grote T, Yee L, Arevalo-Araujo R, Latimer LA.

J Support Oncol. 2006 Oct;4(9):467-71.

PMID:
17080735
13.

Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.

Navari RM.

J Support Oncol. 2003 Jul-Aug;1(2):89-103. Review.

PMID:
15352652
14.
16.

Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials.

Popovic M, Warr DG, Deangelis C, Tsao M, Chan KK, Poon M, Yip C, Pulenzas N, Lam H, Zhang L, Chow E.

Support Care Cancer. 2014 Jun;22(6):1685-97. doi: 10.1007/s00520-014-2175-6. Review.

PMID:
24590374
17.
18.

Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.

Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, Macciocchi A, Grunberg S; 99-04 Palonosetron Study Group..

Cancer. 2003 Dec 1;98(11):2473-82.

19.

Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer.

Navari RM.

Future Oncol. 2010 Jul;6(7):1073-84. doi: 10.2217/fon.10.74. Review.

PMID:
20624119
20.

Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy.

Grunberg SM, Dugan M, Muss H, Wood M, Burdette-Radoux S, Weisberg T, Siebel M.

Support Care Cancer. 2009 May;17(5):589-94. doi: 10.1007/s00520-008-0535-9.

PMID:
19037667
Items per page

Supplemental Content

Support Center